THIS TASK ORDER IS FOR THE PROTEOMIC CHARACTERIZATION LABORATORY.

国家癌症研究所的S临床蛋白质组肿瘤分析联盟是一项全国性的努力，旨在通过应用大规模蛋白质组和基因组分析或蛋白质组学来加速理解癌症的分子基础。NCI支持由Leidos Biomedical Research，Inc(Leidos Biomedical)运营的抗体计划，该计划通过设在马里兰州弗雷德里克的弗雷德里克国家癌症研究实验室(FNLCR)的Leidos Biomed抗体表征实验室(ACL)，全面表征用于癌症研究的亲和试剂。在Leidos BIOMED ACL内，建立了蛋白质组特征实验室(PCL)，用于基于质谱学(MS)的蛋白质组特征(全局蛋白质组和磷酸蛋白质组)和靶向(适合用途的)分析。这份任务单(TO)不仅旨在扩大Leidos BIOMED PCL分析方法的数量，而且还扩大了额外的翻译后修饰(PTM)方法开发的能力，适合用于iMRM和定制测试开发等目的抗体。LEIDOS BIOMED PCL将为CPTAC/DCTD内的项目开发和实施标准化蛋白质组测量(全面的和有针对性的)。LEIDOS BIOMED PCL配备了两台最先进的质谱仪，可为蛋白质和多肽分析提供最佳的灵敏度和准确性，并与CPTAC蛋白质组鉴定中心(PCCs)合作，对蛋白质组能力进行基准测试。NCI研究界将可使用Leidos Bimed PCL来加强转化型癌症研究，优先考虑CPTAC和其他DCTD项目。

The National Cancer Institute (NCI)’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. NCI supports an Antibody Program, operated by Leidos Biomedical Research, Inc (Leidos Biomed), that comprehensively characterizes affinity reagents for cancer research via the Leidos Biomed Antibody Characterization Laboratory (ACL) located at the Frederick National Laboratory for Cancer Research (FNLCR) in Frederick, MD. Within the Leidos Biomed ACL, a Proteome Characterization Laboratory (PCL) was established for comprehensive Mass Spectrometry (MS)-based proteomic characterization (global- and phospho-proteomes) and targeted (fit-for-purpose) assays. This Task Order (TO) aims not only to expand both the number of assays analyzed by the Leidos Biomed PCL, but also broadens the capabilities with method development of additional Post Translational Modifications (PTMs), fit for purpose antibodies for application such as iMRM and custom assay development. The Leidos Biomed PCL will develop and implement standardized proteomic measurements (comprehensive and targeted) for projects within CPTAC/DCTD. The Leidos Biomed PCL is equipped with two state-of-art mass spectrometers to provide the best sensitivity and accuracy for protein and peptide analysis and benchmarked for proteomic competency in coordination with CPTAC Proteome Characterization Centers (PCCs). The Leidos Biomed PCL will be available for the NCI research community to enhance translational cancer research, with priority given to CPTAC and other DCTD programs.